Omar Alqaisi | Skin Cancer | Best Researcher Award

Mr. Omar Alqaisi | Skin Cancer | Best Researcher Award

Al-Zaytoonah University of Jordan | Jordan

Dr. Omar M. Alqaisi is a dedicated academic and researcher at Al-Zaytoonah University of Jordan whose scholarly contributions reflect a strong commitment to advancing healthcare through evidence-based nursing practice and oncology research. With 11 published documents, 46 citations, and an h-index of 3, his work demonstrates a consistent trajectory of academic growth and increasing impact in the fields of clinical nursing, psycho-oncology, and patient-centered care. His notable publication, “A Narrative Review of the Roles of Nursing in Addressing Sexual Dysfunction in Oncology Patients,” underscores his focus on addressing sensitive and underexplored areas of oncology, particularly the psychosocial and emotional well-being of cancer patients, while emphasizing the indispensable role of nurses in holistic recovery and improving quality of life. A hallmark of his career is his emphasis on interdisciplinary collaboration, evidenced by co-authorship with more than 100 researchers across multiple disciplines, reflecting his ability to foster teamwork and integrate diverse perspectives to address complex healthcare challenges. His research is characterized by analytical precision, ethical grounding, and a human-centered approach, aligning with global healthcare trends that prioritize compassion, inclusivity, and evidence-based interventions. Beyond individual studies, Dr. Alqaisi’s work contributes to the broader advancement of nursing education, clinical practice, and patient advocacy in oncology. His growing academic influence positions him as an emerging leader within regional and international research communities. With continued development in empirical methodologies, digital health innovations, and cross-cultural healthcare models, he is poised to expand his contributions to global nursing and oncology discourse. Dr. Alqaisi’s research not only advances academic understanding but also creates meaningful societal impact by emphasizing empathy, communication, and the integration of psychosocial care into clinical frameworks, exemplifying a new generation of scholars committed to bridging scientific innovation with humanistic healthcare practice.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

1. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, October 9). Immune checkpoint inhibitors in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Cancers, 17(19), 3272.

2. Alqaisi, O., Al-Ghabeesh, S., Tai, P., Wong, K., Joseph, K., & Yu, E. (2025, August 14). A narrative review of the roles of nursing in addressing sexual dysfunction in oncology patients. Current Oncology, 32(8), 457.

3. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, July 25). Immunotherapy in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Preprints, 202507.2063.v1.

4. Alqaisi, O., Subih, M., Joseph, K., Yu, E., & Tai, P. (2025, June). Oncology nurses’ attitudes, knowledge, and practices in providing sexuality care to cancer patients: A scoping review. Current Oncology, 32(6), 337.

5. Alqaisi, O. M., & Al-Ghabeesh, S. (2024, July 31). Quality of postoperative pain management in orthopedic patients and its impact on sleep quality and patient satisfaction: An integrative review. Cureus, 16(7), e65872.

Dr. Omar M. Alqaisi’s research advances the integration of compassionate, evidence-based nursing within oncology care, addressing both clinical and psychosocial patient needs. His work strengthens global healthcare practices by promoting interdisciplinary collaboration, enhancing patient quality of life, and shaping innovative models for holistic, human-centered medical care.

Melissa Christiaens | Cervical Cancer | Best Researcher Award

Dr. Melissa Christiaens | Cervical Cancer | Best Researcher Award

Radiation-Oncology | University Hospitals Leuven | Belgium

Dr. Melissa Christiaens is a highly accomplished Radiation Oncologist recognized for her contributions to the advancement of radiotherapy and clinical oncology research. With extensive experience in oncological treatment, she has played a key role in integrating evidence-based radiotherapy techniques into modern cancer care. Her professional expertise spans across radiotherapy quality assurance, pediatric oncology, gynecologic cancers, and multidisciplinary tumor management. As an active member of several leading scientific organizations—including the European Society for Radiotherapy and Oncology, the Paediatric Radiation Oncology Society, the European Society of Gynaecological Oncology, the EuroEwing Consortium, and the Connective Tissue Oncology Society—she consistently collaborates in large-scale international research networks to improve patient outcomes and optimize therapeutic protocols. Her research interests focus on clinical trials in radiotherapy, immuno-oncology integration, and precision treatment strategies for rare and complex cancers. Dr. Christiaens has contributed to numerous high-impact peer-reviewed journals such as The Lancet, Radiotherapy and Oncology, BMC Cancer, and Gynecologic Oncology, where her publications have enhanced the scientific understanding of cancer treatment outcomes, safety, and innovation. Her research skills encompass clinical data interpretation, protocol development, treatment optimization, and evidence synthesis—supported by her commitment to maintaining the highest standards of clinical excellence. Throughout her career, she has demonstrated exceptional leadership in oncology research and education, promoting collaboration and innovation within the global cancer research community. Her achievements continue to inspire advancements in patient-centered cancer therapy and clinical radiobiology. Her enduring scientific legacy is reflected through 1,417 citations, 25 documents, and an h-index of 12, underscoring her influential role in advancing the frontiers of clinical radiotherapy, oncology innovation, and multidisciplinary cancer research.

Featured Publications

1. Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., & Christiaens, M., et al. (2021). MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multicentre prospective cohort study. The Lancet Oncology, 22(4), 538–547. Cited by: 613

2. Zhang, H., Ahearn, T. U., Lecarpentier, J., Barnes, D., Beesley, J., Qi, G., Jiang, X., & Christiaens, M., et al. (2020). Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 52(6), 572–581. Cited by: 466

3. Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., & Christiaens, M., et al. (2024). Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18). The Lancet, 404(10460), 1321–1332. 
Cited by: 323

4. Ajithkumar, T., Horan, G., Padovani, L., Thorp, N., Timmermann, B., Alapetite, C., & Christiaens, M., et al. (2018). SIOPE–Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy. Radiotherapy and Oncology, 128(2), 192–197. Cited by: 113

5. De Ruysscher, D., Sharifi, H., Defraene, G., Kerns, S. L., & Christiaens, M., et al. (2013). Quantification of radiation-induced lung damage with CT scans: The possible benefit for radiogenomics. Acta Oncologica, 52(7), 1405–1410. Cited by: 74

Permal Deo | Prostate Cancer | Best Researcher Award

Dr. Permal Deo | Prostate Cancer | Best Researcher Award

Senior Lecturer | Clinical and Health Sciences, University of South Australia | Australia

Dr. Permal Deo is a distinguished food scientist and academic leader renowned for his contributions to nutrition, food biochemistry, and public health research. He holds a PhD in Food Biochemistry from Queen’s University Belfast, UK, where his doctoral work investigated the effects of food-derived advanced glycation end-products (AGEs) on oxidative stress and receptor activity in human cell lines. Complementing this, he earned a Master of Applied Science and Postgraduate Diploma from The University of Queensland, Australia, and a Bachelor of Science from The University of the South Pacific, Fiji. With over two decades of academic, research, and industry experience, Dr. Deo’s expertise encompasses food microbiology, food processing, functional foods, and the molecular pathways linking type 2 diabetes and Alzheimer’s disease. His research emphasizes the bioactivity of natural plant compounds and nutraceuticals in combating oxidative stress and inflammation, as well as the antimicrobial and food safety applications of electrochemically activated solutions. An accomplished mentor and research leader, he has supervised numerous postgraduate students and attracted more than AUD 2.5 million in competitive funding from prestigious bodies including the Australian Research Council, Diabetes Australia, and Horticulture Innovation. His extensive collaborations with institutions such as CSIRO, Monash University, and the University of Adelaide have advanced understanding in genome stability, indigenous food systems, and sustainable nutrition technologies. Widely recognized for his scholarly impact and leadership, Dr. Deo has presented at global scientific conferences and published influential studies in leading journals. His enduring scientific legacy is reflected through 944 citations, 57 documents, and an h-index of 19, underscoring his influential role in advancing the frontiers of food biochemistry, nutritional science, and biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Snelson, M., Tan, S. M., Clarke, R. E., De Pasquale, C., Thallas-Bonke, V., Deo, P., … & Coughlan, M. T. (2021). Processed foods drive intestinal barrier permeability and microvascular diseases. Science Advances, 7(14), eabe4841. Cited by: 148

2. Sim, D. P., Khazandi, M., Chan, W. Y., Deo, P., & Trott, D. J. (2019). Antimicrobial activity of thyme oil, oregano oil, thymol and carvacrol against sensitive and resistant microbial isolates from dogs with otitis externa. Veterinary Dermatology. Cited by: 106

3. Deo, P., Hewawasam, E., Karakoulakis, A., Claudie, D. J., Nelson, R., & Vemulpad, S. (2016). In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE), and digestive enzymes linked to diabetes. BMC Complementary and Alternative Medicine, 16(1), 435. Cited by: 61

4. Bergamin, A., Mantzioris, E., Cross, G., Deo, P., Garg, S., & Hill, A. M. (2019). Nutraceuticals: Reviewing their role in chronic disease prevention and management. Pharmaceutical Medicine, 33(4), 291–309. Cited by: 60

5. Fenech, M., Knasmueller, S., Knudsen, L. E., Kirsch-Volders, M., Deo, P., … & Bonassi, S. (2021). “Micronuclei and Disease” special issue: Aims, scope, and synthesis of outcomes. Mutation Research/Reviews in Mutation Research, 788, 108384. Cited by: 54

6. Ferro, S., Amorico, T., & Deo, P. (2018). Role of food sanitising treatments in inducing the ‘viable but nonculturable’ state of microorganisms. Food Control, 91, 321–329. Cited by: 54

Ramon Mangues | Cancer | Best Research Article Award

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Rami Ahmad | Cancer Therapy | Best Researcher Award

Prof. Dr. Rami Ahmad | Cancer Therapy | Best Researcher Award

Senior Researcher | Czech Education and Scientific Network | Czech Republic

Prof. Dr. Rami Ahmad El-Nabulsi is a distinguished theoretical physicist and applied mathematician whose research bridges nonlinear quantum dynamics, fractal mechanics, plasma and solid-state physics, and advanced mathematical modeling. Holding a PhD in Particle and Mathematical Physics from AMU, along with postgraduate diplomas in Plasma Physics and degrees in Physics at both master’s and bachelor’s levels, he has built a prolific career combining theoretical rigor with computational innovation. He is currently affiliated with the Center of Excellence in Quantum Technology, Faculty of Engineering, and the Quantum-Atom Optics Laboratory at Chiang Mai University, Thailand, as well as with the University of South Bohemia and the Department of Optical Networks CESNET in the Czech Republic. Prof. El-Nabulsi’s research interests encompass geometrical and quantum dynamics, nonlinear systems, chaos and bifurcations, general relativity, quantum field theory, and the application of fractional and fractal calculus to complex systems in engineering, astrophysics, and materials science. His expertise extends to advanced computational modeling, partial differential equations, stochastic systems, and numerical simulations. He has received multiple international honors, including the Outstanding Scientist Research Award and the Lifetime Achievement Award. A reviewer for more than 250 scientific journals and an editorial board member in over 40 peer-reviewed publications, he has authored more than 390 research articles in high-impact international journals and is frequently invited as an honorary speaker at global conferences. Prof. El-Nabulsi’s academic dedication, multidisciplinary approach, and sustained research excellence continue to shape theoretical and applied physics worldwide. His scholarly impact is reflected in 4,873 citations, 277 documents, and an h-index of 35, underscoring his influential role in advancing modern fractal physics and nonlinear dynamical systems research.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

1. El-Nabulsi, R. A., & Anukool, W. (2025). Chaotic and fractal maps in higher-order derivative dynamical systems. Frontiers in Physics, 12, 1529644. Cited by: 8

2. El-Nabulsi, R. A., & Anukool, W. (2025). Qualitative financial modelling in fractal dimensions. Financial Innovation, 11, 42. Cited by: 6

3. El-Nabulsi, R. A. (2025). A fractional model to study soliton in presence of charged space debris at low-Earth orbital plasma region. IEEE Transactions on Plasma Science, 52(9), 4671–4693. Cited by: 4

4. El-Nabulsi, R. A., & Golmankhaneh, A. K. (2025). Propagation of waves in fractal spaces. Waves in Random and Complex Media. Cited by: 4

5. El-Nabulsi, R. A., & Anukool, W. (2025). Vlasov equation, waves and dispersion relations in fractal dimensions: Landau damping and the toroidal ion temperature gradient instability problem. Waves in Random and Complex Media. Cited by: 14

6. El-Nabulsi, R. A. (2024). Transition from circular to spiral waves and from Mexican hat to upside-down Mexican hat-solutions: The cases of local and nonlocal λ–ω reaction–diffusion–convection fractal systems with variable coefficients. Chaos, Solitons & Fractals, 189, 115737. Cited by: 3

7. El-Nabulsi, R. A. (2024). Modelling nematic liquid crystal in fractal dimensions. Medicine in Novel Technology and Devices, 24, 100334. Cited by: 7

Hongyu li | Breast Cancer | Best Researcher Award

Hongyu li | Breast Cancer | Best Researcher Award

Xinjiang medical university | China

AUTHOR PROFILE

SCOPUS

🎓EARLY ACADEMIC PURSUITS 

Assoc. Prof. Dr. Hongyu Li embarked on her academic journey at Xinjiang Medical University, where she earned her Doctor of Medicine degree and subsequently completed a Ph.D. in 2021. Her formative years were marked by rigorous academic training and an early interest in the oncology of breast diseases, which laid the foundation for her future specialization in breast cancer metastasis research.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently serving as an Associate Professor, Associate Chief Physician, and Doctor of Medicine at the Department of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Dr. Li brings over a decade of clinical expertise to the field. Her clinical focus is on the early detection, diagnosis, and management of breast cancer. She has been honored with prestigious awards including the “Tianchi Talent” Youth Doctor Award (2022), the Outstanding Postdoctoral Special Funding (2023), and was selected for the “789 Talent” Training Program (2024), cementing her reputation as a High-Level Talent and Outstanding Young Physician.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER 

Dr. Li’s scientific inquiry is anchored in understanding the molecular mechanisms of breast cancer metastasis, with a specific focus on breast cancer brain metastasis (BCBM)—a critical and poorly understood manifestation associated with poor prognosis. Her translational research bridges clinical challenges and bench-side investigations, aiming to identify novel biomarkers and potential therapeutic targets for BCBM.

She adopts an integrative approach that translates clinical observations into mechanistic questions, enhancing the effectiveness of future treatments and diagnostic strategies for late-stage breast cancer.

📚IMPACT AND INFLUENCE 

Dr. Li’s work is contributing to shaping the clinical paradigms in breast cancer care within the Xinjiang region and beyond. Her research is improving understanding of metastatic processes, especially in underrepresented ethnic populations. She is also involved in institutional collaborations and has served in editorial capacities, reinforcing her influence in both academic and clinical oncology spheres.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Looking forward, Dr. Li aims to establish a dedicated translational research unit focused on metastatic breast cancer, particularly BCBM. She is committed to mentoring young researchers and expanding interdisciplinary collaborations that bridge molecular oncology with precision medicine. Her ultimate goal is to redefine treatment algorithms and enhance survival outcomes for patients with advanced-stage breast cancer.

🌍CONCLUSION 

Assoc. Prof. Dr. Hongyu Li stands as a beacon of translational oncology, seamlessly integrating clinical care with cutting-edge research. Her relentless pursuit of knowledge, commitment to public health, and strategic focus on a critically unmet need in oncology make her a deserving nominee for the Best Researcher Award.

 

📊🔬NOTABLE PUBLICATION:

Title: GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway

Authors: Hongyu Li, Yalin Zhang, Xiao Han, Bingyu Li, Dan Liu, Gang Sun

Journal: Scientific Reports (Nature Publishing Group)

Year: 2025

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

MPMMCC, HBCH,Tata memorial centreVaranasi | India

AUTHOR PROFILE

GOOGLE SCHOLAR

🎓 EARLY ACADEMIC PURSUITS

Dr. Sadaf Haiyat laid a strong foundation for her medical career at Aligarh Muslim University (AMU), one of India’s premier institutions. She completed her MBBS in 2011 and pursued her MD in Pathology, graduating in 2016 with distinction. Her early education was marked by academic excellence, securing 75.5% in SSSC (10+2) with a distinction in Chemistry, and scoring a 99% merit in Science during high school at Nazareth Academy, Gaya.

🧑‍🏫 PROFESSIONAL ENDEAVORS

Dr. Haiyat has accrued over 11 years of rich experience in Anatomic and Clinical Pathology, including senior roles across reputed institutions such as J.N.M.C.H, AMU, Popular Multispeciality Hospital (Varanasi), Dr. Lal Path Labs (New Delhi), and currently serves as Assistant Professor and Consultant Oncopathologist at the Tata Memorial Centre/MPMMCC, Varanasi.

Her journey has spanned clinical diagnostics, academic teaching, lab administration, and quality assurance. She played a pivotal role in establishing a molecular pathology lab and actively leads EQAS audits and CAP/NABL compliance efforts.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON HEMATOLYMPHOID MALIGNANCY

Dr. Haiyat has significantly contributed to the diagnosis and characterization of hematolymphoid malignancies, integrating morphological, immunohistochemical, molecular, and cytogenetic techniques. She has independently handled bone marrow biopsies, hematopathology diagnostics, and real-time PCR testing, including for EGFR, HER2/neu, and EWSR1 alterations. Her role in initiating molecular diagnostics for precision oncology marks a critical contribution to personalized medicine in resource-optimized settings.

📚 ACADEMIC CONTRIBUTIONS AND CITES

  • Total Publications: 25 (including 19 in international journals)

  • Presentations: 34 papers/posters at national and international platforms

  • Conferences Attended: 44 (10 international, 34 national)

  • Notable Thesis: “Role of Syndecan-1 (CD138) as a Diagnostic Biomarker for Plasma Cells in Patients of Abnormal Uterine Bleeding”

Her research is regularly cited in hematology and oncopathology contexts, particularly for rare case diagnostics and biomarker identification.

🌏 IMPACT AND INFLUENCE

Her academic and diagnostic influence extends internationally, evidenced by:

  • Membership in prestigious bodies such as the International Society of Gynecological Pathology, Association of Molecular Pathology (AMP), and the British Association of Urologic Pathology.

  • Awarded the 2024 Global Pathology Education Award by the College of American Pathologists (CAP) — a global recognition of excellence and commitment to medical education and diagnostics.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Haiyat’s legacy is anchored in diagnostic precision, academic mentoring, and laboratory excellence. With a growing footprint in digital pathology, molecular diagnostics, and oncopathology, she is poised to lead next-generation pathology services, potentially extending to AI-assisted diagnostics, genomics-based therapeutic mapping, and international collaborations in cancer diagnostics.

She also mentors senior residents and scientific assistants, reflecting her commitment to nurturing the next wave of medical professionals.

🔚 CONCLUSION

Dr. Sadaf Haiyat stands out as a visionary pathologist, blending diagnostic expertise with academic vigor and clinical leadership. Her journey from a meritorious student to a recognized name in oncopathology reflects a commitment to excellence, education, and innovation. With a robust foundation, international accolades, and an eye toward the future of molecular and digital pathology, Dr. Haiyat is undeniably shaping the landscape of modern diagnostic medicine in India and beyond.

📊NOTABLE PUBLICATION:

Breast lymphomas: Clinical and pathological insights from a tertiary cancer care center in India
Journal: Indian Journal of Pathology and Microbiology
Year: 2024


Megaloblastic anemia: A common but often neglected cause of pyrexia of unknown origin
Journal: Journal of Translational Internal Medicine
Year: 2015


Epithelioid sarcoma: A diagnostic challenge of a rare presentation
Journal: Archives of International Surgery
Year: 2016


A Survey of Intestinal Lesions with Special Reference to Intestinal Tuberculosis in and Around Uttar Pradesh, India
Journal: International Journal of Current Microbiology and Applied Sciences
Year: 2015


Extradigital Glomus Tumour of Ankle in a Toddler: A Rare Case Report with Unusual Presentation
Journal: Journal of Medical and Surgical Pathology
Year: 2018

Dr. Yaqin Wu | Carcinoma | Women Researcher Award

Dr. Yaqin Wu | Carcinoma | Women Researcher Award

Hunan provincial people’s hospital | China

AUTHOR PROFILE

Scopus

🌟Wu Yaqin 

🏥CURRENT ROLES AND AFFILIATIONS 

  • Current Position: Organizational Committee Member, Graduate Student Party Branch
  • Graduate Institution: Hunan Provincial People’s Hospital (Hunan Normal University First Affiliated Hospital), Breast and Thyroid Surgery, Master’s Supervisor: Professor Zhang Chaojie
  • Undergraduate Institution: Hunan Normal University Medical School, Clinical Medicine (2014.9–2019.6)

📚EARLY ACADEMIC PURSUITS 

Wu Yaqin began her academic journey at Hunan Normal University Medical School, excelling in Clinical Medicine. Her undergraduate years were marked by stellar academic performance, with scholarships awarded every year, including National Scholarship and National Inspirational Scholarship.

🔬PROFESSIONAL ENDEAVORS 

Currently pursuing a Master’s degree in Surgery (Breast and Thyroid Surgery) at Hunan Provincial People’s Hospital, Wu has honed her clinical and research skills. She has gained recognition for:

  1. Outstanding clinical rotation performance.
  2. Active participation in surgeries, assisting in level 3 and 4 operations.
  3. Representing her hospital in Clinical Skills Competitions.

🧪CONTRIBUTIONS AND RESEARCH FOCUS 

Wu Yaqin has a strong foundation in research and innovation, focusing on:

  • Scientific Techniques: Proficiency in WB, PCR, single-cell sequencing, metabolomics, and other experimental skills.
  • Data Analysis: Skilled in SPSS, bioinformatics, and advanced statistical analysis.
  • Publications:
    • 2 SCI papers as the first and corresponding author (Cumulative Impact Factor: 5.143).
    • 2 core journal publications in China.
  • Research Projects:
    • Contributed to two provincial-level projects and two horizontal projects as the lead researcher (under mentor guidance).

🌟IMPACT AND INFLUENCE 

Wu’s contributions extend beyond academia:

  • Regularly earns recognition as an Outstanding Party Member, Student, and Graduate.
  • Actively involved in expert consensus compilation, adding to professional guidelines.
  • Participates in large-scale event organization with exceptional planning and execution skills.

PERSONAL SKILLS AND INTERESTS 🎙️

  • Language Proficiency:
    • Passed CET-4 and CET-6.
    • Achieved Grade 2-A in the National Mandarin Test.
  • Technical Skills:
    • Proficient in basic and advanced experimental techniques.
    • Skilled in computer applications (provincial-level certification).
  • Special Interests: Broadcasting, hosting, debate, and recitation.

RECOGNITION AND HONORS 🏅

During Master’s Program:

  • Authored high-impact research papers.
  • Contributed to prestigious projects and received multiple awards for academic excellence.

During Undergraduate Program:

  • Awarded numerous scholarships and honors.
  • Served in various leadership roles:
    • Vice Minister, Learning Department of the Student Union.
    • Captain, Debate Team.
    • Psychological Committee Member, Class Representative.

LEGACY AND FUTURE CONTRIBUTIONS 🌐

Wu Yaqin’s dedication to clinical excellence, innovative research, and effective communication positions her as a rising star in medical sciences. She is committed to:

  1. Advancing clinical practice and surgical expertise.
  2. Expanding her impact through cutting-edge research and mentorship roles.
  3. Building a legacy of leadership and service within the medical community.

 

📊🔬NOTABLE PUBLICATION:
  • 1. LncRNA SNHG5 promotes the glycolysis and proliferation of breast cancer cell through regulating BACH1 via targeting miR-299
    • Authors: Huang, S.-L., Huang, Z.-C., Zhang, C.-J., Wu, Y.-Q., Fan, P.-Z.
    • Journal: Breast Cancer
    • Year: 2022

    2. The expression and meaning of CD68, CD163, CD57, and IgG4 in granulomatous lobular mastitis

    • Authors: Kong, C., Zhang, C., Wu, Y., He, J., Fan, P.
    • Journal: Gland Surgery
    • Year: 2020

    3. miRNA-195-5p/PSAT1 feedback loop in human triple-negative breast cancer cells

    • Authors: Wang, H., Fang, Q., You, S., Wu, Y., Zhang, C.
    • Journal: Genes and Genomics
    • Year: 2023

    4. Value of dissection of lymph nodes posterior to the right recurrent laryngeal nerve in patients with cN0 papillary thyroid carcinoma

    • Authors: Xiao, X., Wu, Y., Zou, L., Chen, Y., Zhang, C.
    • Journal: Gland Surgery
    • Year: 2022

    5. A clinical observation of stage I implant breast reconstruction for mass-like granulomatous lobular mastitis

    • Authors: Zhang, C., Wu, Y., Wang, H., Li, Q., Fan, P.
    • Journal: Gland Surgery
    • Year: 2021

Dr. Jinyu Zhang | Hepatocellular Carcinoma | Best Researcher Award

Dr. Jinyu Zhang | Hepatocellular Carcinoma | Best Researcher Award

Fujian Medical University | China

AUTHOR PROFILE

Scopus

JINYU ZHANG: ACADEMIC JOURNEY AND PROFESSIONAL IMPACT

🎓EARLY ACADEMIC PURSUITS

Jinyu Zhang began their academic journey in Clinical Medicine Science at Fujian Medical University, where they pursued a rigorous undergraduate program from September 2014 to June 2019. This foundational education equipped Jinyu with a strong understanding of medical principles, diagnostics, and patient care. Their dedication to excellence during these formative years laid the groundwork for a promising career in medicine.

💼ADVANCED EDUCATION AND SPECIALIZATION

Building upon their undergraduate achievements, Jinyu Zhang pursued a Master’s degree in Surgery at Fujian Medical University from September 2019 to June 2022. This phase marked a significant transition to specialized training, allowing them to deepen their expertise in surgical techniques, patient management, and clinical research.

Currently, Jinyu is enrolled in a Doctoral program in Surgery at Fujian Medical University, which they began in September 2022. This ongoing pursuit highlights their commitment to advancing medical science and refining their clinical acumen.

🔬PROFESSIONAL ENDEAVORS

Throughout their academic career, Jinyu Zhang has shown a consistent interest in combining theoretical knowledge with practical application. Their professional endeavors include:

  • Clinical Rotations: Active participation in diverse hospital departments during their undergraduate and master’s studies to gain hands-on experience.
  • Surgical Training: Specialized focus on improving surgical outcomes and patient recovery rates.
  • Research Collaborations: Involvement in multidisciplinary projects to enhance surgical methodologies and innovate treatment strategies.

🌍CONTRIBUTIONS AND RESEARCH FOCUS ON HEPATOCELLULAR CARCINOMA

Jinyu Zhang’s research primarily focuses on:

  • Minimally Invasive Surgical Techniques: Exploring innovative approaches to reduce patient recovery time and improve procedural efficiency.
  • Post-Surgical Care Optimization: Studying ways to enhance post-operative outcomes through better patient management and intervention strategies.
  • Surgical Training and Education: Developing frameworks to improve surgical education for aspiring surgeons.

Their work bridges the gap between research and practical application, contributing to advancements in the field of surgery.

📚IMPACT AND INFLUENCE

Jinyu Zhang’s contributions to clinical medicine and surgery have started gaining recognition among peers and mentors. Their innovative ideas have the potential to shape future surgical practices and improve patient care standards. Through conference presentations and research publications, Jinyu has actively participated in disseminating knowledge to the medical community.

🔮ACADEMIC CITATIONS

Jinyu Zhang’s academic work is increasingly being cited by peers, demonstrating its relevance and impact in the field of surgery. These citations reflect the quality and applicability of their research in addressing contemporary challenges in surgical practice.

🏆LEGACY AND FUTURE CONTRIBUTIONS

As Jinyu Zhang progresses in their Doctoral studies and continues to refine their skills and research expertise, their legacy is likely to include:

  • Innovative Surgical Techniques: Introduction of new methods that could revolutionize surgical procedures.
  • Mentorship: Inspiring and guiding the next generation of medical students and researchers.
  • Collaborative Contributions: Partnering with global medical institutions to advance the field of surgery.

🌟CONCLUSION

Jinyu Zhang’s journey from a dedicated medical student to an emerging expert in surgery exemplifies a blend of academic rigor and professional ambition. Their research focus, contributions to surgical science, and commitment to patient care position them as a future leader in the field. With ongoing efforts, they are poised to leave an indelible mark on medical practice and research.

 

📊🔬NOTABLE PUBLICATION:
    1. Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma: a multicenter study from China
      • Authors: Chen, Y.; Liu, H.; Zhang, J.; …; Zeng, Y.; Liu, J.
      • Journal: BMC Cancer
      • Year: 2021

    1. Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study
      • Authors: Wu, Y.; Liu, H.; Zeng, J.; …; Zeng, Y.; Liu, J.
      • Journal: World Journal of Surgical Oncology
      • Year: 2022

    1. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients
      • Authors: Lin, K.-Y.; Lin, Z.-W.; Chen, Q.-J.; …; Yang, T.; Zeng, Y.-Y.
      • Journal: Hepatology International
      • Year: 2023

    1. Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis
      • Authors: Kong, J.; Liang, X.; Zhang, J.; …; Liu, J.; Zeng, J.
      • Journal: Digestive Diseases and Sciences
      • Year: 2022

    1. Prognostic significance of three-tiered pathological classification for microvascular invasion in patients with combined hepatocellular-cholangiocarcinoma following hepatic resection
      • Authors: Wu, Y.; Liu, H.; Chen, Y.; …; Zeng, Y.; Liu, J.
      • Journal: Cancer Medicine
      • Year: 2023

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Stanford University School of Medicine | United States

Author Profile

Scopus

Orcid id

📚 Biography: Dr. Stavros Melemenidis

🎓 Education

  • DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
    • Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
    • Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
  • M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
  • M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
  • B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
  • A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
  • Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

🏢 Current Position

  • Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
  • Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

🔬 Research Experience & Skills

  • Stanford University, Dept. Radiation Oncology, Stanford, CA
    • Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
      • Calibration of preclinical orthovoltage irradiators
      • Monthly and annual quality checks for dosimetric consistency
      • Innovation in animal radiation shielding via 3D design and additive manufacturing
    • Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
      • Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
      • Specializing in 3D-designed radiation shielding for animal safety
      • Expertise in dosimetry using radiochromic film and ion chambers
      • Development of animal models involving tumor implantation and microsurgical techniques
    • Postdoctoral Fellow (Feb 2016-Jun 2020)
      • Advisor: Edward E. Graves
      • Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
      • Specialized in ultrasound-guided injection techniques
      • Conducted research into immune cell migration with a focus on macrophage imaging
      • Evaluated radioprotective strategies for healthy tissue through drug development
    • Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
      • Advisor: Nicola R. Sibson
      • Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
      • Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
      • Managed international research collaboration with Duke University

📜 Selected Publications

  • In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
  • Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
  • Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
  • Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

🏆 Awards & Honors

  • Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
  • Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

🗣️ Conference Presentations

  • Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
  • Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

📞 References

  • Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
  • Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
  • Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

📊🔬Notable Publication: